Precision Neurology Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Precision Neurology Market 

5.1. COVID-19 Landscape: Precision Neurology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Precision Neurology Market, By Technology

8.1. Precision Neurology Market, by Technology

8.1.1. Genomics

8.1.1.1. Market Revenue and Forecast

8.1.2. Proteomics

8.1.2.1. Market Revenue and Forecast

8.1.3. Biomarker-based Diagnostics

8.1.3.1. Market Revenue and Forecast

8.1.4. AI & Machine Learning Analytics

8.1.4.1. Market Revenue and Forecast

8.1.5. Neuroimaging Technologies

8.1.5.1. Market Revenue and Forecast

Chapter 9. Global Precision Neurology Market, By Therapeutic Area

9.1. Precision Neurology Market, by Therapeutic Area

9.1.1. Alzheimer’s Disease

9.1.1.1. Market Revenue and Forecast

9.1.2. Parkinson’s Disease

9.1.2.1. Market Revenue and Forecast

9.1.3. Multiple Sclerosis

9.1.3.1. Market Revenue and Forecast

9.1.4. Epilepsy

9.1.4.1. Market Revenue and Forecast

9.1.5. Amyotrophic Lateral Sclerosis (ALS)

9.1.5.1. Market Revenue and Forecast

9.1.6. Autism Spectrum Disorders

9.1.6.1. Market Revenue and Forecast

9.1.7. Stroke

9.1.7.1. Market Revenue and Forecast

9.1.8. Other Neurological Disorders

9.1.8.1. Market Revenue and Forecast

Chapter 10. Global Precision Neurology Market, By Application 

10.1. Precision Neurology Market, by Application

10.1.1. Personalized Diagnostics

10.1.1.1. Market Revenue and Forecast

10.1.2. Precision Therapeutics

10.1.2.1. Market Revenue and Forecast

10.1.3. Drug Discovery & Development

10.1.3.1. Market Revenue and Forecast

10.1.4. Disease Risk Prediction

10.1.4.1. Market Revenue and Forecast

10.1.5. Patient Stratification

10.1.5.1. Market Revenue and Forecast

10.1.6. Monitoring & Prognostics

10.1.6.1. Market Revenue and Forecast

Chapter 11. Global Precision Neurology Market, By End-use

11.1. Precision Neurology Market, by End-use

11.1.1. Hospitals

11.1.1.1. Market Revenue and Forecast

11.1.2. Specialty Neurology Clinics

11.1.2.1. Market Revenue and Forecast

11.1.3. Academic & Research Institutes

11.1.3.1. Market Revenue and Forecast

11.1.4. Pharmaceutical & Biotechnology Companies

11.1.4.1. Market Revenue and Forecast

11.1.5. Diagnostic Laboratories

11.1.5.1. Market Revenue and Forecast

Chapter 12. Global Precision Neurology Market, By Delivery Model

12.1. Precision Neurology Market, by Delivery Model

12.1.1. Hospital-based Precision Neurology

12.1.1.1. Market Revenue and Forecast

12.1.2. Cloud-based Neurology Platforms

12.1.2.1. Market Revenue and Forecast

12.1.3. Cloud-based Neurology Platforms

12.1.3.1. Market Revenue and Forecast

Chapter 13. Global Precision Neurology Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Technology

13.1.2. Market Revenue and Forecast, by Therapeutic Area

13.1.3. Market Revenue and Forecast, by Application

13.1.4. Market Revenue and Forecast, by End-use

13.1.5. Market Revenue and Forecast, by Delivery Model

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Technology

13.1.6.2. Market Revenue and Forecast, by Therapeutic Area

13.1.6.3. Market Revenue and Forecast, by Application

13.1.6.4. Market Revenue and Forecast, by End-use

13.1.6.5. Market Revenue and Forecast, by Delivery Model  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Technology

13.1.7.2. Market Revenue and Forecast, by Therapeutic Area

13.1.7.3. Market Revenue and Forecast, by Application

13.1.7.4. Market Revenue and Forecast, by End-use

13.1.7.5. Market Revenue and Forecast, by Delivery Model

13.2. Europe

13.2.1. Market Revenue and Forecast, by Technology

13.2.2. Market Revenue and Forecast, by Therapeutic Area

13.2.3. Market Revenue and Forecast, by Application

13.2.4. Market Revenue and Forecast, by End-use  

13.2.5. Market Revenue and Forecast, by Delivery Model  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Technology

13.2.6.2. Market Revenue and Forecast, by Therapeutic Area

13.2.6.3. Market Revenue and Forecast, by Application

13.2.7. Market Revenue and Forecast, by End-use  

13.2.8. Market Revenue and Forecast, by Delivery Model  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Technology

13.2.9.2. Market Revenue and Forecast, by Therapeutic Area

13.2.9.3. Market Revenue and Forecast, by Application

13.2.10. Market Revenue and Forecast, by End-use

13.2.11. Market Revenue and Forecast, by Delivery Model

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Technology

13.2.12.2. Market Revenue and Forecast, by Therapeutic Area

13.2.12.3. Market Revenue and Forecast, by Application

13.2.12.4. Market Revenue and Forecast, by End-use

13.2.13. Market Revenue and Forecast, by Delivery Model

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Technology

13.2.14.2. Market Revenue and Forecast, by Therapeutic Area

13.2.14.3. Market Revenue and Forecast, by Application

13.2.14.4. Market Revenue and Forecast, by End-use

13.2.15. Market Revenue and Forecast, by Delivery Model

13.3. APAC

13.3.1. Market Revenue and Forecast, by Technology

13.3.2. Market Revenue and Forecast, by Therapeutic Area

13.3.3. Market Revenue and Forecast, by Application

13.3.4. Market Revenue and Forecast, by End-use

13.3.5. Market Revenue and Forecast, by Delivery Model

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Technology

13.3.6.2. Market Revenue and Forecast, by Therapeutic Area

13.3.6.3. Market Revenue and Forecast, by Application

13.3.6.4. Market Revenue and Forecast, by End-use

13.3.7. Market Revenue and Forecast, by Delivery Model

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Technology

13.3.8.2. Market Revenue and Forecast, by Therapeutic Area

13.3.8.3. Market Revenue and Forecast, by Application

13.3.8.4. Market Revenue and Forecast, by End-use

13.3.9. Market Revenue and Forecast, by Delivery Model

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Technology

13.3.10.2. Market Revenue and Forecast, by Therapeutic Area

13.3.10.3. Market Revenue and Forecast, by Application

13.3.10.4. Market Revenue and Forecast, by End-use

13.3.10.5. Market Revenue and Forecast, by Delivery Model

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Technology

13.3.11.2. Market Revenue and Forecast, by Therapeutic Area

13.3.11.3. Market Revenue and Forecast, by Application

13.3.11.4. Market Revenue and Forecast, by End-use

13.3.11.5. Market Revenue and Forecast, by Delivery Model

13.4. MEA

13.4.1. Market Revenue and Forecast, by Technology

13.4.2. Market Revenue and Forecast, by Therapeutic Area

13.4.3. Market Revenue and Forecast, by Application

13.4.4. Market Revenue and Forecast, by End-use

13.4.5. Market Revenue and Forecast, by Delivery Model

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Technology

13.4.6.2. Market Revenue and Forecast, by Therapeutic Area

13.4.6.3. Market Revenue and Forecast, by Application

13.4.6.4. Market Revenue and Forecast, by End-use

13.4.7. Market Revenue and Forecast, by Delivery Model

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Technology

13.4.8.2. Market Revenue and Forecast, by Therapeutic Area

13.4.8.3. Market Revenue and Forecast, by Application

13.4.8.4. Market Revenue and Forecast, by End-use

13.4.9. Market Revenue and Forecast, by Delivery Model

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Technology

13.4.10.2. Market Revenue and Forecast, by Therapeutic Area

13.4.10.3. Market Revenue and Forecast, by Application

13.4.10.4. Market Revenue and Forecast, by End-use

13.4.10.5. Market Revenue and Forecast, by Delivery Model

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Technology

13.4.11.2. Market Revenue and Forecast, by Therapeutic Area

13.4.11.3. Market Revenue and Forecast, by Application

13.4.11.4. Market Revenue and Forecast, by End-use

13.4.11.5. Market Revenue and Forecast, by Delivery Model

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Technology

13.5.2. Market Revenue and Forecast, by Therapeutic Area

13.5.3. Market Revenue and Forecast, by Application

13.5.4. Market Revenue and Forecast, by End-use

13.5.5. Market Revenue and Forecast, by Delivery Model

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Technology

13.5.6.2. Market Revenue and Forecast, by Therapeutic Area

13.5.6.3. Market Revenue and Forecast, by Application

13.5.6.4. Market Revenue and Forecast, by End-use

13.5.7. Market Revenue and Forecast, by Delivery Model

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Technology

13.5.8.2. Market Revenue and Forecast, by Therapeutic Area

13.5.8.3. Market Revenue and Forecast, by Application

13.5.8.4. Market Revenue and Forecast, by End-use

13.5.8.5. Market Revenue and Forecast, by Delivery Model

Chapter 14. Company Profiles

14.1. F. Hoffmann-La Roche Ltd.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Biogen Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Novartis AG

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Pfizer Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Eli Lilly and Company

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. AbbVie Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Thermo Fisher Scientific

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Illumina Inc

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Qiagen N.V.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Siemens Healthineers

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms